EX-99.1 2 ss2718111_ex9901.htm JOINT FILING AGREEMENT

 

 

Exhibit 1

JOINT FILING AGREEMENT

 

The undersigned hereby agree that Amendment No. 2 to Schedule 13D, dated November 14, 2023 with respect to the Ordinary Shares and American Depository Shares of Chemomab Therapeutics Ltd. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

 

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 15th day of November 2023.

 

  By:  /s/ Carl L. Gordon  
    Name: Carl L. Gordon  
       
  By: /s/ Erez Chimovits  
    Name: Erez Chimovits  
       
  ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP
       
  By: OrbiMed Israel GP Ltd., its General Partner  
       
  By:  /s/ Carl L. Gordon  
    Name: Carl L. Gordon  
    Title: Director  
       
  ORBIMED ISRAEL GP LTD.   
       
  By:  /s/ Carl L. Gordon  
    Name: Carl L. Gordon  
    Title: Director